REGEND001 Autologous Basal Layer Stem Cell is named as a drug or biological intervention in 2 clinical trials in our China trial register, 2 of which are recruiting. The lead sponsor is Ruijin Hospital. Registered phase: Phase 1. Conditions studied include Interstitial Lung Disease (ILD); Bronchiectasis Adult.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06987214 | REGEND001 Autologous Basal Layer Stem Cell Transplantation for Bronchiectasis: A Translational Application Study (ClinicalTrials.gov ↗) Bronchiectasis Adult |
Phase 1 | Recruiting |
| NCT06998706 | REGEND001 Autologous Basal Layer Stem Cell Transplantation for Interstitial Lung Disease (ILD): A Translational Application Study (ClinicalTrials.gov ↗) Interstitial Lung Disease (ILD) |
Phase 1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Interstitial Lung Disease (ILD) | 1 |
| Bronchiectasis Adult | 1 |
| Lead sponsor | Trials |
|---|---|
| Ruijin Hospital | 2 |
| Register | REGEND001 Autologous Basal Layer Stem Cell trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how REGEND001 Autologous Basal Layer Stem Cell works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists REGEND001 Autologous Basal Layer Stem Cell (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.